TITANBIO.BO BSE
Titan Biotech Limited
1W: -1.4%
1M: -0.9%
3M: +0.6%
YTD: +89.6%
1Y: -11.0%
3Y: +18.6%
5Y: +17.1%
₹383.10 ($3.98)
-8.40 (-2.15%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$2.1B
+31.8% ▲
5Y CAGR: +7.7%
Gross Profit
$727M
-13.3% ▼
5Y CAGR: +1.7%
Operating Income
$337M
+58.4% ▲
5Y CAGR: -5.4%
Net Income
$299M
+38.8% ▲
5Y CAGR: -0.3%
EPS (Diluted)
$7.23
+38.8% ▲
5Y CAGR: -27.7%
EBITDA
$386M
+31.6% ▲
5Y CAGR: -3.6%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.4B | $1.6B | $1.6B | $2.1B |
| YoY Growth | -13.1% | +16.6% | +13.9% | -4.6% | +31.8% |
| Cost of Revenue | $705M | $856M | $1.2B | $726M | $1.3B |
| Gross Profit | $530M | $584M | $433M | $838M | $727M |
| Gross Margin | 42.9% | 40.5% | 26.4% | 53.6% | 35.3% |
| R&D Expenses | $0 | $967K | $1M | $0 | $0 |
| SG&A Expenses | $66M | $96M | $112M | $310M | $390M |
| Operating Expenses | $241M | $314M | $117M | $626M | $390M |
| Operating Income | $292M | $518M | $316M | $213M | $337M |
| Operating Margin | 23.7% | 36.0% | 19.3% | 13.6% | 16.3% |
| Interest Expense | $9M | $7M | $12M | $8M | $9M |
| Income Before Tax | $290M | $319M | $315M | $276M | $406M |
| Tax Expense | $73M | $71M | $79M | $61M | $107M |
| Net Income | $217M | $248M | $249M | $215M | $299M |
| Net Margin | 17.6% | 17.3% | 15.1% | 13.8% | 14.5% |
| EPS (Diluted) | $26.24 | $30.06 | $30.07 | $5.21 | $7.23 |
| EBITDA | $320M | $315M | $358M | $293M | $386M |
| Shares Outstanding | 8M | 8M | 8M | 41M | 41M |